title: [Prognostic analyses of occult breast cancer].
abstract: OBJECTIVE
  To explore the prognosis of occult breast cancer.
  
  
  METHODS
  From January 1978 to December 2008, retrospective analyses were conducted for 205 female patients with axillary lymph node metastasis from an unknown primary source.
  
  
  RESULTS
  During a median follow-up time of 61 (4-158) months, the 5 and 10-year rates of disease-free survival (DFS) were 63.5% and 39.8% respectively. The median overall survival (OS) was 10 years. And the 5 and 10-year OS were 79.8% and 49.4% respectively. Significant differences existed in medical history, family history, estrogen receptor (ER), human epidermal growth factor receptor-2 (HER-2), infiltration of soft tissue, surgical option, neoadjuvant chemotherapy, chemotherapy, and radiotherapy with DFS of occult breast cancer (P < 0.05). The most important determinants of DFS and OS were ER, infiltration of soft tissue and neoadjuvant chemotherapy (P < 0.05).
  
  
  CONCLUSIONS
  Radical mastectomy should be performed instead of modified radical mastectomy to improve the patient quality of life.
authors.affiliation: Third Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment Research Center, Tianjin Medical University Cancer Institute & Hospital; Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education; Key Laboratory of Cancer Prevention & Therapy, Tianjin 300060, China.
authors.forename: Xiaomeng
authors.initials: X
authors.lastname: Hao
authors.affiliation: Third Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment Research Center, Tianjin Medical University Cancer Institute & Hospital; Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education; Key Laboratory of Cancer Prevention & Therapy, Tianjin 300060, China.
authors.forename: Sheng
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Third Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment Research Center, Tianjin Medical University Cancer Institute & Hospital; Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education; Key Laboratory of Cancer Prevention & Therapy, Tianjin 300060, China.
authors.forename: Jingjing
authors.initials: J
authors.lastname: Liu
authors.affiliation: Third Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment Research Center, Tianjin Medical University Cancer Institute & Hospital; Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education; Key Laboratory of Cancer Prevention & Therapy, Tianjin 300060, China.
authors.forename: Min
authors.initials: M
authors.lastname: Zhang
authors.affiliation: Third Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment Research Center, Tianjin Medical University Cancer Institute & Hospital; Key Laboratory of Breast Cancer Prevention and Therapy of Ministry of Education; Key Laboratory of Cancer Prevention & Therapy, Tianjin 300060, China. Email: zhangjin@tjmuch.com.
authors.forename: Jin
authors.initials: J
authors.lastname: Zhang
mesh_terms: D001365:Axilla; D001943:Breast Neoplasms; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes; D008207:Lymphatic Metastasis; D015411:Mastectomy, Modified Radical; D020360:Neoadjuvant Therapy; D011379:Prognosis; D011788:Quality of Life; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D012189:Retrospective Studies
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human